Summary
VTRS Chart
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Q4 EPS Tops, Brands Drive Revenue Growth, Stock Up
VTRS beats Q4 estimates on 5% revenue growth, boosted by strong Brands sales and Greater China gains, while returning over $1B to shareholders in 2025.
Viatris (VTRS) Surpasses Q4 Earnings and Revenue Estimates
Viatris (VTRS) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of $0.52 per share. This compares to earnings of $0.54 per share a year ago.
Viatris Inc. (VTRS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
What is the earnings per share?
When is the next earnings date?
Has Viatris Inc. ever had a stock split?
Viatris Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Scott Andrew Smith CEO | XWBO Exchange | US92556V1061 ISIN |
| US Country | 32,000 Employees | 9 Mar 2026 Last Dividend | 9 Oct 2003 Last Split | 16 Nov 2020 IPO Date |
Overview
Viatris Inc. is a global healthcare company that has marked its presence worldwide since its foundation in 1961, with its headquarters situated in Canonsburg, Pennsylvania. The company operates across various segments globally, including Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. Viatris is committed to providing access to medicines, sustainable operations, and community support, focusing on addressing the needs of patients in both noncommunicable and infectious disease domains. Its wide array of products stretches from prescription brand drugs to complex generics, biosimilars, and active pharmaceutical ingredients (APIs), catering to a broad spectrum of therapeutic areas and underpinning its mission to empower people worldwide to live healthier at every stage of life.
Products and Services
Viatris Inc.'s expansive portfolio encompasses a diverse range of healthcare solutions, from critical medicines to comprehensive support services, aimed at enhancing patient care and access:
- Prescription Brand Drugs & Generics: Includes essential medications for various health conditions, ensuring patients have access to quality treatment options.
- Complex Generic Drugs: Offers complex generics that are equivalent to brand-name drugs, providing more accessible and cost-effective treatment alternatives.
- Biosimilars: The company produces biosimilars for oncology, immunology, endocrinology, ophthalmology, and dermatology, offering high-quality alternatives to existing biologic drugs.
- Active Pharmaceutical Ingredients (APIs): APIs for a vast range of therapeutic areas including antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors, highlighting the breadth of Viatris’s capabilities in drug manufacturing.
- Support Services: Beyond just providing medications, Viatris also facilitates diagnostic clinics, educational seminars, and digital tools to help individuals better manage their health, emphasizing the holistic approach to healthcare.
Medications are delivered in various forms, including oral solid doses, injectables, and complex dosage forms, ensuring versatility in administration ways to suit different patient needs. Distribution channels encompass pharmaceutical wholesalers/distributors, retailers, institutional pharmacies, mail-order, e-commerce, and specialty pharmacies, ensuring broad accessibility. Products like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and the EpiPen auto-injector, among others, highlight the wide range and significance of Viatris’s offering in addressing global health issues. Through partnerships, like with Revance Therapeutics, Inc. and Momenta Pharmaceuticals, Inc., Viatris Inc. continues to expand its portfolio, promising innovation and expanded access to essential medicines for patients worldwide.
